Drugs that contain Patisiran Sodium

1. List of Onpattro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(2 years from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(9 months from now)

US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(9 months from now)

US8642076 ALNYLAM PHARMS INC Lipid containing formulations
Oct, 2027

(4 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation
Oct, 2030

(7 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 10, 2025
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic